The designers of heart disease trials should ensure that they recruit enough women to reveal reliably whether they are responding to the drugs in a different way from men, according to research published on line today (Tuesday, 2 August) in Europes leading cardiology journal, the European Heart Journal.
Women are under represented in most clinical studies, so the data and the results are less well documented for them, according to Dr Verena Stangl, senior author of the paper, who is from the Charité Hospital, Humboldt-University Berlin, Germany.
Dr Stangl, who is Professor of Cardiology (Molecular Atherosclerosis) at the hospitals Department of Cardiology, Angiology and Pneumology, said that although the percentage of women in studies of coronary heart disease had risen since the mid 1980s to reflect the prevalence of CHD in women, they were still under represented in trials involving coronary artery disease, arterial hypertension and heart failure.
"Because too few women participate in heart disease trials we are not sure whether they really benefit from some therapeutic strategies that have shown clinical benefit in trials conducted predominantly in men. So, we prescribe drugs to women adapted from evidence-based data obtained from studies conducted mainly in men and we do not really know whether we help or harm the female patients. Take one example: as we have no prospective data for digitalis in female patients, its unclear whether it is really linked to increased mortality among women or whether this increase is an effect only of an overdose, and therefore whether they would benefit from lower doses adapted to their weight."
Dr Stangl said women have historically been under-represented in trials. The main reason was probably because cardiovascular diseases have erroneously been perceived as male diseases. As most cardiovascular diseases tend to occur later in women, co-existing health problems and age limitations on trials have worked against their inclusion. Late diagnosis due to different and more ambiguous symptoms was another reason and, for women of child-bearing age, the risks of damaging a foetus if a woman became pregnant, led to exclusion.
Dr Stangls call for increasing the numbers of women in heart trials is backed in an editorial also published in EHJ on line today by specialists from the University of Pavia in Italy.
Senior author Dr Silvia Priori, Associate Professor of Cardiology at the University of Pavia, said that research published this year showed that of 300 new drug applications to the US Food and Drug Administration (FDA) between 1995 and 2000 only 163 included an analysis according to gender. Yet 11 of the drugs involved showed a difference in the way a womans body dealt with the drugs compared with a mans (the pharmacokinetics).
"These differences underlie the importance of studying women as well as men in major cardiovascular trials. Most of the progress in this direction has occurred in the USA as a direct consequence of the commitment of funding agencies that have provided economic support only when a balanced gender presence was assured in the design of a trial," said Dr Priori.
She urged scientific societies to play a major role in ensuring trials investigate gender- specific response to therapy. The Europe Society of Cardiology (ESC), which publishes the European Heart Journal, recently developed the Women at Heart programme to organise initiatives targeted at promoting research and education in cardiovascular disease in women.
The ESC Congress in Stockholm (3-7 September) will focus specially on women and cardiovascular diseases, said Dr Priori, and the ESC is to perform gender-based analyses of data in the Euro Heart Survey – the programme that monitors clinical practice in Europe. She added that, in future, the ESC will work to promote a larger representation of women in clinical trials to provide missing data on gender differences in response to drug therapy.
 Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. European Heart Journal. doi: 101093/eurheartj/ehi397.
 Gender-specific prescription for cardiovascular diseases? European Heart Journal. doi: 10.1093/eurheartj/ehi428.
Margaret Willson | alfa
Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine
University of Maryland researchers contribute to historic detection of gravitational waves and light created by event
On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...
Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.
Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....
Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).
When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...
Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.
How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...
Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.
It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...
17.10.2017 | Event News
10.10.2017 | Event News
10.10.2017 | Event News
20.10.2017 | Interdisciplinary Research
20.10.2017 | Materials Sciences
20.10.2017 | Earth Sciences